SB1096: Preserve Access to Affordable Generics and Biosimilars Act
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Plain-language summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
SB1096: Preserve Access to Affordable Generics and Biosimilars Act
Upcoming hearings & events
Sponsors
Amy Klobuchar
Primary SponsorCo-sponsors (8)
Chuck Grassley
Richard Durbin
Kevin Cramer
Richard Blumenthal
Joni Ernst